Treatment and outcomes of immune checkpoint inhibitors-associated colitis/diarrhea: A systematic review and meta-analysis
Digestive and Liver Disease · 2023
DOI: 10.1016/j.dld.2023.02.016 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Digestive and Liver Disease, 2023. Verfasst von Min Ding und 6 weiteren Autor:innen. Beteiligte Einrichtung: Meta-Analysis Interest Group, Department of Gastroenterology, The General Hospital of Northern Theater Command (formerly General Hospital of Shenyang…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Colitis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Immune checkpoint inhibitors (ICIs) have improved the outcomes of cancer patients. However, ICIs often lead to colitis/diarrhea. This study aimed to assess the treatment of ICIs-associated colitis/diarrhea and outcomes. METHODS: PubMed, EMBASE, and Cochrane Library databases were searched for eligible studies which investigated the treatment and outcomes of colitis/diarrhea developing in patients who received ICIs. The pooled incidences of any-grade colitis/diarrhea, low-grade colitis, high-grade colitis, low-grade diarrhea, and high-grade diarrhea as well as the pooled rates of response to treatment, mortality, and ICIs permanent discontinuation and restarts in patients with ICIs-associated colitis/diarrhea were estimated using a random-effects model. RESULTS: Among the 11,492 papers initially identified, 27 studies were included. The pooled incidences of any-grade colitis/diarrhea, low-grade colitis, high-grade colitis, low-grade diarrhea, and high-grade diarrhea were 17%, 3%, 17%, 13%, and 15%, respectively. The pooled rates of overall response, response to corticosteroid therapy, and response to biological agents were 88%, 50%, and 96%, respectively. The pooled short-term mortality in patients with ICIs-associated colitis/diarrhea was 2%. The pooled incidences of ICIs permanent discontinuation and restarts were 43% and 33%, respectively. CONCLUSION: ICIs-associated colitis/diarrhea is common, but rarely lethal. Half of them are responsive to corticosteroid therapy. There is a fairly high rate of response to biological agents in steroid-refractory colitis/diarrhea patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Meta-Analysis Interest Group, Department of Gastroenterology, The General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area), Shenyang, China; Postgraduate College, China Medical…
- Meta-Analysis Interest Group, Department of Gastroenterology, The General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area), Shenyang, China; Department of Life Sciences and Biop…
- Meta-Analysis Interest Group, Department of Gastroenterology, The General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area), Shenyang, China; Department of Gastroenterology, The…
- Clinical Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Zitieren
APA
Ding, M., Zhang, X., Wang, J., Gao, F., Zheng, X., Yuan, J., & Qi, X. (2023). Treatment and outcomes of immune checkpoint inhibitors-associated colitis/diarrhea: A systematic review and meta-analysis. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2023.02.016
Vancouver
Ding M, Zhang X, Wang J, Gao F, Zheng X, Yuan J, et al. Treatment and outcomes of immune checkpoint inhibitors-associated colitis/diarrhea: A systematic review and meta-analysis. Digestive and Liver Disease. 2023. doi:10.1016/j.dld.2023.02.016
BibTeX
@article{Ding2023,
author = {Ding, Min and Zhang, Xianxian and Wang, Jing and Gao, Fangbo and Zheng, Xiaojie and Yuan, Jinqiu and Qi, Xingshun},
title = {Treatment and outcomes of immune checkpoint inhibitors-associated colitis/diarrhea: A systematic review and meta-analysis},
journal = {Digestive and Liver Disease},
year = {2023},
doi = {10.1016/j.dld.2023.02.016}
}
EUVIMED